NASDAQ:CRBPCorbus Pharmaceuticals Stock Price, Forecast & News

Corbus Pharmaceuticals' stock was trading at $4.12 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CRBP stock has increased by 81.6% and is now trading at $7.48. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Corbus Pharmaceuticals.

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Corbus Pharmaceuticals.

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) released its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.03. The biopharmaceutical company had revenue of $1.76 million for the quarter, compared to the consensus estimate of $1.64 million. Corbus Pharmaceuticals had a negative net margin of 207.87% and a negative return on equity of 282.91%. View Corbus Pharmaceuticals' earnings history.

5 analysts have issued twelve-month target prices for Corbus Pharmaceuticals' shares. Their forecasts range from $12.00 to $112.00. On average, they anticipate Corbus Pharmaceuticals' stock price to reach $39.80 in the next year. This suggests a possible upside of 432.1% from the stock's current price. View analysts' price targets for Corbus Pharmaceuticals.

News stories about CRBP stock have trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Corbus Pharmaceuticals earned a news sentiment score of 0.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutCorbus Pharmaceuticals.

Some companies that are related to Corbus Pharmaceuticals include Prestige Consumer Healthcare (PBH), SAGE Therapeutics (SAGE), IGM Biosciences (IGMS), Epizyme (EPZM), Pacira Biosciences (PCRX), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL), Xencor (XNCR), Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Corcept Therapeutics (CORT), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Ligand Pharmaceuticals (LGND) and Arvinas (ARVN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Exelixis (EXEL), Viveve Medical (VIVE), Canopy Growth (CGC), Western Digital (WDC), Cronos Group (CRON) and Zynerba Pharmaceuticals (ZYNE).

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Corbus Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.96%), ETF Managers Group LLC (4.92%), Pinnacle Associates Ltd. (1.69%), State Street Corp (1.60%), Geode Capital Management LLC (1.37%) and Morgan Stanley (1.07%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Craig Stuart Millian, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen. View institutional ownership trends for Corbus Pharmaceuticals.

CRBP stock was sold by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, AdvisorShares Investments LLC, UBS Group AG, Raymond James & Associates, Morgan Stanley, Morgan Stanley, AE Wealth Management LLC, and Virtus ETF Advisers LLC. View insider buying and selling activity for Corbus Pharmaceuticals.

CRBP stock was acquired by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Carmignac Gestion, DAFNA Capital Management LLC, BlackRock Inc., Geode Capital Management LLC, General American Investors Co. Inc., Alpine Global Management LLC, and Nuveen Asset Management LLC. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, Craig Stuart Millian, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran, and Yuval Cohen. View insider buying and selling activity for Corbus Pharmaceuticals.

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRBP stock can currently be purchased for approximately $7.48.

Corbus Pharmaceuticals has a market capitalization of $542.23 million and generates $36.14 million in revenue each year. The biopharmaceutical company earns $-71,450,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Corbus Pharmaceuticals employs 141 workers across the globe.

The official website for Corbus Pharmaceuticals is www.corbuspharma.com.

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]